The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with rheumatic diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: First Hospital of Jilin University; The First Hospital of Jilin University
• Treatments: Aldesleukin; Interleukin-2

Criteria

Inclusion Criteria:

1. age <18 years old

2. meet the diagnostic criteria of disease classification

3. HIV negative;Negative for Hepatitis B Virus and Hepatitis C Virus.

Exclusion Criteria:

1. heart failure (cardiac function ≥ grade III NYHA)

2. liver insufficiency (upper limit of normal range of transaminase > 2 times)

3. renal insufficiency (creatinine clearance ≤30ml/min)

4. acute or severe infections such as bacteremia and sepsis

5. malignant tumor

6. high-dose steroid pulse therapy or intravenous injection of glucocorticoids in the last 1 month;Rituximab, infliximab or other biological agents were used

7. mental disorders or any other chronic illness or substance abuse may interfere with the ability to comply with agreements or provide information

8. Inability to comply with IL-2 treatment regimen.